What is the best antibiotic for Mycoplasma pneumoniae?

Several types of antibiotics are effective. Antibiotics that are used to treat walking pneumonia caused by Mycoplasma pneumoniae include: Macrolide antibiotics: Macrolide drugs are the preferred treatment for children and adults. Macrolides include azithromycin (Zithromax®) and clarithromycin (Biaxin®).

Does azithromycin cure mycoplasma?

While treatment-failure in M. genitalium–positive NGU appears common with doxycycline (4,7–11), early reports suggest 1 g azithromycin is more effective, with cure rates of 85% (10,11), and that prolonged azithromycin treatment (500 mg on day 1 and 250 mg on days 2–5) eradicates M. genitalium in 95% of cases (10).

What is the treatment for Mycoplasma pneumoniae?

What is the treatment for mycoplasma infection? Antibiotics such as erythromycin, clarithromycin or azithromycin are effective treatment. However, because mycoplasma infection usually resolves on its own, antibiotic treatment of mild symptoms is not always necessary.

Which drug is not recommended for treating pneumonia caused from Mycoplasma pneumoniae?

Clinicians should not prescribe fluoroquinolones and tetracyclines for young children under normal circumstances. Macrolides are generally considered the treatment of choice. However, clinicians should practice prudent use of macrolide drugs due to the emergence of macrolide-resistant strains of M. pneumoniae.

How long can azithromycin be given for pneumonia?

Azithromycin is equally effective as treatment of atypical pneumonia in adult patients if given for 3 or 5 days at the same total dose. Publication types Comparative Study

Can a Mycoplasma pneumoniae be treated with antibiotics?

Most M. pneumoniae infections are self-limiting; however, clinicians routinely treat pneumonia caused by Mycoplasma pneumoniae with antibiotics. All mycoplasmas lack a cell wall and, therefore, all are inherently resistant to beta-lactam antibiotics (e.g., penicillin).

What are the clinical features of Mycoplasma pneumoniae?

The clinical presentation of M. pneumoniae respiratory disease is often similar to what is seen with other atypical pathogens, particularly Chlamydia pneumoniae, various respiratory viruses and bacteria.

Is there any resistance to Mycoplasma pneumoniae in the US?

This issue is especially troubling in Asia, where resistance rates have been as high as 90%. The United States and Europe have also reported macrolide resistance. Current data suggest that the prevalence of macrolide resistance in M. pneumoniae may be around 10% in the United States, with regional variability.